Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.
Alvotech’s shares are set to begin trading on the Nasdaq First North Growth Market exchange on 23 June, after the pure play biosimilar company’s request for admission of its shares in its domestic Iceland was approved.
The firm’s admission is subject to publication of Alvotech’s company description in accordance with the Nasdaq First North Growth Market...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
